In a paper published in Arthritis and Rheumatism, Bendtzen & coworkers used Biomonitor’s RIA’s for infliximab/Remicade® and anti-infliximab Ab to monitor RA patients. They demonstrated the high frequency of patients with Ab, and they showed that development of antibodies, heralded by low pre-infusion serum-infliximab levels, is associated with increased risk of infusion reactions and treatment failure. They conclude that early monitoring helps optimize dose regimens to individual patients, diminishes side-effects and prevents prolonged use of inadequate infliximab therapy.

Download the paper here